Unmet medical needs are not infrequent in oncology, and these needs are
usually of higher magnitude in rare cancers. The field of neuroendocrine
neoplasms (NENs) has evolved rapidly during the last decade, and,
currently, a new WHO classification is being implemented and several
treatment options are available in the metastatic setting after the
results of prospective phase III clinical trials. However, several
questions are still unanswered, and decisions in our daily clinical
practice should be made with limited evidence. In the 2016 meeting of
the advisory board of the European Neuroendocrine Tumor Society (ENETS),
the main unmet medical needs in the metastatic NENs setting were deeply
discussed, and several proposals to try to solve them are presented in
this article, including biomarkers, imaging, and therapy
